舒绍坤  研究员

邮箱: shaokun_shu@bjmu.edu.cn

教育背景

1999-2003 本科，生物工程，北京理工大学

2005-2010 博士，分子肿瘤学，美国南佛罗里达大学

工作经历

2003.8 – 2005.8: 中科院基因组所， 研究助理

2011.1 – 2011.8： 美国南佛罗里达大学， 博士后

2011.8 – 2019.8： 哈佛医学院Dana-Farber 肿瘤研究中心， 博士后/讲师

2019.9 – 北京大学国际癌症研究院/北京大学肿瘤医院，研究员

研究领域

肿瘤表观遗传学, 靶向治疗, 肿瘤微环境，联合用药，高通量基因编辑筛选（CRISPR Screen）.

获奖情况

2017, Jon Shevell Young Scientist Scholarship, Keyston Epigenetics symposium, Seattle.

2016, Jon Shevell Young Scientist Scholarship, Cold Spring Harbor Annual Meeting, New York.

2015, AACR Breast Cancer training award, AACR Breast Cancer Annual Meeting, Seattle.

2010, Travel award and oral presentation, American Association for Cancer Research, Mini-symposium

项目资助

2014, Susan Komen Breast Cancer Foundation Postdoc Fellowship, $180,000

2019-2021，临床医学+X青年项目：BET抑制剂在胃癌中的转化研究

2021-2024，教育部长江学者青年计划

2022-2025，国自然面上项目：BET抑制剂在胃癌中的作用机制和生物标志物

2022-2024，人社部高层次留学人才资助

个人研究介绍

南佛罗里达大学博士毕业，哈佛大学医学院/Dana-Farber肿瘤研究所Polyak实验室从事博士后研究工作,2019年9月加入北京大学医学部。主要从事肿瘤表观遗传学的转化研究，通过结合多组学手段和高通量功能基因组筛选平台，研究肿瘤微环境，鉴定了三阴性乳腺癌重要靶点基因， 进行靶向药物临床前试验，研究其作用机理，并进一步研究了肿瘤对靶向药物的抗药性机理，找到克服肿瘤抗药性的联合用药方案，启动临床试验。近年来，研究论文以第一作者发表在Nature，Molecular Cell等杂志，一项国际专利，启动和参与两项二期临床实验，课题获得两项研究经费资助,4次国际会议获奖，2次国际会议口头报告。把靶向药物BET抑制剂应用到三阴性乳腺癌治疗，启动了二期临床试验，同时启动了BET抑制剂联合免疫治疗（PD-L1抗体），BET抑制剂联合CDK4/6抑制剂的临床试验，研究成果被新闻媒体广泛报道，包括Nature News & Views，Faculty of 1000和 GEN (Genetic Engineering & Biotechnology News)。

发表文章

1. Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak K. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020 May 7. pii: S1097-2765(20)

2. Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, Brown M, Sicinski P, McDonald TO, Pellman D, Michor F, Polyak K. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020 May 11;11(1):2350.

3. Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer EP, Letai A, Barry WT, Carroll JS, Long HW, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K. Response and resistance to BET bromodomain inhibitors in triple negative breast cancer. Nature. 2016; 529: 413–417.

4. Shu S, Polyak K. BET Bromodomain Proteins as Cancer Therapeutic Targets. Cold Spring Harbor Symposia on Quantitative Biology. 2016;81:123-129.

5. Janiszewska M, Tabassum DP, Castaño Z, Cristea S, Yamamoto KN, Kingston NL, Murphy KC, Shu S, Harper NW, Del Alcazar CG, Alečković M, Ekram MB, Cohen O, Kwak M, Qin Y, Laszewski T, Luoma A, Marusyk A, Wucherpfennig KW, Wagle N, Fan R, Michor F, McAllister SS, Polyak K. Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2019 Jul;21(7):879-888.

6. Witwicki RM, Ekram MB, Qiu X, Janiszewska M, Shu S, Kwon M, Trinh A, Frias E, Ramadan N, Hoffman G, Yu K, Xie Y, McAllister G, McDonald R, Golji J, Schlabach M, deWeck A, Keen N, Chan HM, Ruddy D, Rejtar T, Sovath S, Silver S, Sellers WR, Jagani Z, Hogarty MD, Roberts C, Brown M, Stegmaier K, Long H, Shivdasani RA, Pellman D, Polyak K. TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Reports. 2018 Oct 30;25(5):1255-1267

7. Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research. 2016 Nov 15;76(22):6495-6506.